Drug Transporter (DT) Information

General Information of DT
DT ID DTD0129
Gene Name SLC1A1
Protein Name Excitatory amino acid transporter 3
Gene ID
6505
UniProt ID
P43005
TCDB ID
2.A.23.2.3
3D Structure

Modelled DT Structure

Method: loop building

Template PDB: 6S3Q_A

Identity: 98.763%

Minimized Score: -1266.824 kcal/mol

Detail: Structure Info

Synonyms DCBXA; EAAC1; EAAT3; Excitatory amino-acid carrier 1; Neuronal and epithelial glutamate transporter; SCZD18; SLC1A1; Sodium-dependent glutamate/aspartate transporter 3; Solute carrier family 1 member 1
DT Family Dicarboxylate/Amino Acid:Cation (Na(+) Or H(+)) Symporter (DAACS) Family ;
Tissue Specificity Expressed in all tissues tested includingliver, muscle, testis, ovary, retinoblastoma cell line, neuronsand brain (in which there was dense expression in substantianigra, red nucleus, hippocampus and in cerebral cortical layers).
Function This sodium-dependent, high-affinity amino acid transporter functions as a symporter and mediates the uptake of L-glutamate and also L-aspartate and D-aspartate. Can also transport L-cysteine. Mediates Cl(-) flux that is not coupled to amino acid transport; this avoids the accumulation of negative charges due to aspartate and Na(+) symport. Plays an important role in L-glutamate and L-aspartate reabsorption in renal tubuli. Plays a redundant role in the rapid removal of released glutamate from the synaptic cleft, which is essential for terminating the postsynaptic action of glutamate.
Endogenous Substrate(s) Cysteine; Potassium ions; Li+; Na+; Aspartate
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 3.0)

(β) Post-translational Modification of This DT
Post-translational Modification (PTM)

(γ) Transcriptional Regulation of This DT
Transcriptional Regulation (TSR)

(δ) Epigenetic Regulation of This DT
Epigenetic Regulation (EGR)

(ε) Exogenous Modulation of This DT
Exogenous Modulation (EGM)

Structural Variability Data of This DT (VARIDT 2.0)

(α) Mutation-induced Structural Variation
Mutation-induced Structural Variation (MSV)

(β) Inter-species Structural Differences
Inter-species Structural Differences (ISD)

(γ) Outward/inward-facing Conformation
Outward/inward-facing Conformation (OIC)

(δ) Xenobiotics-regulated Structural Variability
Xenobiotics-regulated Structural Variability (XSV)

General Variability Data of This DT (VARIDT 1.0)

(α) Genetic Polymorphisms of This DT
Genetic Polymorphisms of This DT (GPD)

(β) Disease-specific Protein Abundances of This DT
Disease-specific Protein Abundances of This DT (DPAD)

(γ) Species- and Tissue-specific DT Abundances
Species/Tissue-specific Protein Abundances of This DT (S/TPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Approved Drug

 Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
L-glutamic acid
 Approved Drug Info Schizophrenia 6A20 [1]

Drug-DT Affinity Assessed by Cell Line

 Approved Drug

 Click to Show/Hide the Full List of Drug:            2 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
L-glutamic acid Approved Drug Info Human embryonic kidney cells (HEK293)-EAAT3 Km = 9.9 microM [2]
L-glutamic acid Approved Drug Info Human embryonic kidney cells (HEK293)-EAAT3 Km = 25 microM [3]
References
1 Loss-of-function mutations in the glutamate transporter SLC1A1 cause human dicarboxylic aminoaciduria. J Clin Invest. 2011 Jan;121(1):446-53.
2 Stereoselective chemoenzymatic synthesis of the four stereoisomers of l-2-(2-carboxycyclobutyl)glycine and pharmacological characterization at human excitatory amino acid transporter subtypes 1, 2, and 3. J Med Chem. 2006 Nov 2;49(22):6532-8.
3 Chemoenzymatic synthesis of a series of 4-substituted glutamate analogues and pharmacological characterization at human glutamate transporters subtypes 1-3. J Med Chem. 2005 Dec 15;48(25):7980-92.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.